

# SATELLITE SYMPOSIA

PACIFICO

DAY 1  
**MAY 10**

**OPEN TO ALL**

The management of joint health in patients with Hemophilia A with and without inhibitors

*WFH session supported by Takeda*



12:45  
to  
13:45

DAY 2  
**MAY 11**

**HCP ONLY**

Higher levels for better joints: Changes in the landscape of joint health preservation in patients with haemophilia A

*Sanofi/Sobi*

**sanofi**

 sobi

18:00  
to  
19:00

**HCP ONLY**

Gene therapy for hemophilia A and the impact on musculoskeletal health

*BioMarin*

**B:OMARIN**

DAY 3  
**MAY 12**

**OPEN TO ALL**

Joint Health in People with Hemophilia (PWH)

*WFH session supported by Pfizer*



**WFH COMPREHENSIVE CARE SUMMIT**

# The management of joint health in patients with hemophilia A with and without inhibitors

MAY 10, 2023 | 12:45 - 13:45 ART  
PACIFICO

*WFH session supported by Takeda*



Joint health is critical to overall quality of life for PWH, with and without inhibitors. This symposium will introduce evidence from real-world studies to highlight the impact of hemophilia A on the normal functioning of joints, and the consequences of joint damage over time. Learn special considerations for orthopedic surgeons to keep in mind when undertaking surgical interventions in patients with inhibitors, and how the presence of inhibitors can impact the management and outcome of surgical procedures. Discover how HCPs can collaborate with patients and their families to develop personalized treatment care plans, and how advances in technology and advanced clinical trials impact the delivery and effectiveness of these strategies.

## **Chair**

*Margareth C. Ozelo, Professor, Hemocentro Unicamp, University of Campinas, Brazil*

## **Presenters**

*Margareth C. Ozelo, Professor, Hemocentro Unicamp, University of Campinas, Brazil*

*GianLuigi Pasta, Orthopedist, Fondazione IRCCS Policlinico San Matteo Pavia, Italy*

*Waander Van Heerde, Academic Clinical Assistant, Hematology, Radboudumc, HTC-NEM, Netherlands*

# Gene therapy for hemophilia A and the impact on musculoskeletal health

---

MAY 10, 2023 | 18:00 - 19:00 ART  
PACIFICO

*BioMarin*

**B:OMARIN**<sup>®</sup>

This session will focus on a three-year analysis of a prospective longitudinal study evaluating the impact of gene therapy with valoctocogene roxaparvovec on the musculoskeletal (MSK) health of patients with severe hemophilia A

## **Moderator**

*Margareth C. Ozelo, Professor, Hemocentro Unicamp, University of Campinas, Brazil*

## **Presenter**

*Gabriela Yamaguti-Hayakawa, Hematologist, Hemocentro UNICAMP / University of Campinas, Campinas, Brazil*

# Higher levels for better joints: Changes in the landscape of joint health preservation in patients with haemophilia A

MAY 11, 2023 | 12:45 - 13:45 ART  
PACIFICO

Sanofi/Sobi

**sanofi**

**sobi**

This medical educational symposium, organized by Sanofi and Sobi, is intended for healthcare professionals and will focus on the joint health of people with haemophilia. Although annualized bleed rates approach zero with current treatments, joint damage still occurs. This symposium will examine the impact of poor joint health on people with haemophilia, the role of the multidisciplinary team in helping to diagnose subclinical joint bleeds using physical examination and imaging techniques, evidence supporting prophylaxis with higher factor levels as a joint protection strategy, and the challenges of joint surgery.

## **Chair**

*Margareth C. Ozelo, Professor, Hemocentro Unicamp, University of Campinas, Brazil*

## **Presenters**

*David Stephensen, Physiotherapist, East Kent Hospitals, University NHS Foundation Trust and Royal London Hospital, London, United Kingdom*

*Andrea Doria, Professor, University of Toronto, Toronto, Canada*

*Davide Matino, Assistant Professor, McMaster University, Hamilton, Canada*

*Robert Klamroth, Director, Department for Internal medicine - Vivantes Klinikum im Friedrichshain, Berlin, Germany*

# Joint health in people with hemophilia (PWH)

MAY 12, 2023 | 12:45 - 13:45 ART  
PACIFICO

*WFH session supported by Pfizer*



Joint damage is the most common complication of bleeding in hemophilia. Join this symposium to learn strategies to cope with episodic bleeds versus a prophylactic approach, and how the results compare in the muscle and joint bleed. Learn how to detect early joint damage and develop strategies for the management of arthropathy in its different stages to maintain functionality of the joint. Compare joint health in both developed and developing countries, and discover functional assessments which can be performed in both circumstances. Uncover physiotherapy treatment approaches to maintain ankle joint health and the recommendations for evaluation of joint health from childhood to adulthood.

## **Chair**

*Daniela Neme, Medical Director, Foundation of Hemophilia, Argentina*

## **Presenters**

*Daniela Neme, Medical Director, Foundation of Hemophilia, Argentina*

*Horacio Caviglia, Professor of Orthopaedic Surgery, Buenos Aires University, Argentina*

*Sébastien Lobet, Physiotherapist & Researcher, Cliniques universitaires Saint-Luc, Belgium*